Lunch Details
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) is a clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases, with an initial focus on Multiple System Atrophy (MSA). MSA is a rare, rapidly progressive condition with no approved disease-modifying therapy. The company's lead candidate, ATH434, demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Following its End-of-Phase 2 meeting with the FDA, Alterity is preparing to start a single pivotal Phase 3 trial. The Company is based in Melbourne, with a US office in San Francisco.
